Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy. (3rd September 2019)

• Record Type: Journal Article
• Authors: Asaka, Ryoichi; Le, Anne
• Is Part Of: Molecular & cellular oncology. Volume 6:Number 5(2019)
• Publication Date: 2019-09-03
• Subjects: N-acetyl-aspartyl-glutamate (NAAG) -- glutamate carboxypeptidase II (GCPII) -- glutaminase inhibitor -- glutamate reservoir -- stable isotope-resolved metabolomics (SIRM); Tumors -- Periodicals; Neoplasms; Periodicals; 616.99
• DOI: 10.1080/23723556.2019.1627273
• Languages: English
• ISSNs: 2372-3556

Abstract

ABSTRACT: We uncovered the neurotransmitter N-acetyl-aspartyl-glutamate (NAAG) as a reservoir providing glutamate to promote cancer growth, and demonstrated that inhibition of NAAG hydrolysis by targeting glutamate carboxypeptidase II is a viable strategy for cancer therapy. Our study also suggests that NAAG concentration in plasma could be a non-invasive measurement to monitor cancer progression.